Vivo Bio Tech Receives Upgraded Stock Call

Vivo Bio Tech, a microcap pharmaceutical company, has recently received an upgraded stock call from MarketsMOJO. The company's stock has been upgraded to 'Hold' on January 2nd, 2024.
The technical trend of the stock has improved from Mildly Bullish to Bullish, with both MACD and Bollinger Band technical factors showing positive signs. Additionally, the company has a ROCE of 11, making it a very attractive valuation with a 1.1 Enterprise value to Capital Employed.

Despite the recent increase in stock price, Vivo Bio Tech is still trading at a discount compared to its average historical valuations. In the past year, the stock has generated a return of 33.81%, while its profits have risen by 139.3%. This is reflected in the company's low PEG ratio of 0.2.

It is worth noting that the majority of shareholders in Vivo Bio Tech are non-institutional investors. This may indicate a lack of confidence from larger, more experienced investors.

However, the company does have some weak long-term fundamental strength, with a -2.81% CAGR growth in net sales over the last 5 years. In the most recent quarter, the company's net sales were at its lowest at Rs 9.26 crore.

Overall, while the technical trend and valuation of Vivo Bio Tech are positive, the company's weak long-term fundamental strength and majority non-institutional shareholders may be cause for concern. Investors should carefully consider all factors before making any decisions regarding this microcap pharmaceutical company.